Physician profile
Mindy A Augustine
NPI 1881792091
$751.21
in general payments reported to CMS, 2019-2025
22 companies · $265 in 2025
The $265 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $91.44 · 2023: $210 · 2024: $185 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $659.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $153.04 | 2025 | Phasix Mesh |
| Janssen Biotech, INC. | $76.97 | 2022-2025 | Rybrevant, Darzalex, Tecvayli |
| Seagen INC. | $55.09 | 2023 | Adcetris, Padcev |
| Stemline Therapeutics INC. | $46.06 | 2023-2024 | Orserdu |
| Csl Behring | $43.05 | 2022-2025 | Afstyla, Idelvion |
| Genmab U.S., INC. | $41.67 | 2024-2025 | Epkinly |
| Octapharma USA, INC. | $41.56 | 2024-2025 | Octagam Immune Globulin (Human) |
| Array Biopharma INC | $34.03 | 2023 | Mektovi, Lorbrena, Braftovi |
| Kite Pharma, INC. | $27.12 | 2023 | Yescarta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.06 | 2024 | |
| Alexion Pharmaceuticals, INC. | $22.15 | 2025 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $21.20 | 2025 | Iclusig |
| Pharmacosmos Therapeutics INC. | $19.96 | 2024 | Cosela |
| Abbvie INC. | $19.95 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $19.87 | 2024 | Imfinzi |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $19.35 | 2024 | Xpovio |
| Genentech USA, INC. | $18.42 | 2022 | |
| Pfizer INC. | $14.16 | 2023 | |
| Taiho Oncology, INC. | $13.96 | 2024 | |
| Ge Healthcare | $13.61 | 2022 | |
| Astellas Pharma US INC | $13.53 | 2024 | Xospata |
| Mirati Therapeutics, INC. | $13.40 | 2023 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mindy Augustine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.